Early-Stage Choroidal Melanoma
AURAAura Biosciences IncCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Belzupacap Sarotalocan (Bel-sar) in Early-Stage Choroidal Melanoma. The expected timing is based on the latest available company guidance and may change.
CoMpass trial. 12/7/23- Dosed 1st patient. 3/24/25- Ongoing enrollment. 8/13/25- Complete enrollment by YE 2025. 11/13/25:- Updated Ph3 CoMpass guidance; enrollment now expected to complete in 2026 and topline 15-month primary endpoint data in Q4 2027. 03/30/26:- CoMpass enrollment now expected to complete Mid-2026; topline 15-month data guidance updated to H2 2027. 05/11/26:- Ph3 CoMpass enrollment expected to complete Mid-2026; topline 15-month data anticipated in H2 2027. 06/01/26:- CoMpass Ph3 enrollment completed (108). Topline 15-month primary endpoint data anticipated H2 2027. 08/11/26:- CoMpass Ph3 enrollment and H2 2027 topline data guidance were reiterated.
Verification
Confirm timing and program details against the company announcement or filing.